par Anna Heim | Avr 7, 2023 | EC Europe, EC Newsletter, EC venture capital, scandinavia, Startups, TechStars, The Exchange, venture, Y Combinator, Y Combinator Winter 2023
When The Exchange wrote about Sweden’s startup scene at the end of last month, we said we’d revisit the Nordics this week. Well, a promise is a promise. But after spending hours watching YC’s Winter 2023 Demo Day pitches this week, we also... par Anna Heim | Mar 30, 2023 | EC Newsletter, EC venture capital, startup accelerators, Startups, stockholm, Sweden, TechStars, The Exchange
As the global venture capital market contracts following a historic investing boom, the downturn impacts each startup market differently. While we’ve given the United States’ startup ecosystem most of our attention lately, it’s time to broaden our perspective. And... par Alex Wilhelm | Mar 14, 2023 | EC Newsletter, EC venture capital, Startups, TechStars, The Exchange, Y Combinator
Amid the Silicon Valley Bank-led chaos of the last few days, Y Combinator made an intriguing announcement: It’s pivoting away from late-stage investing. It won’t be the last venture group to pull back from an expansion of its traditional investing remit.... par Alex Wilhelm | Mar 14, 2023 | EC Newsletter, EC venture capital, Startups, TechStars, The Exchange, Y Combinator
Amid the Silicon Valley Bank-led chaos of the last few days, Y Combinator made an intriguing announcement: It’s pivoting away from late-stage investing. It won’t be the last venture group to pull back from an expansion of its traditional investing remit.... par Lauren Simonds | Fév 3, 2023 | Funding, Startups, TechCrunch Early Stage, TechStars
Information is power, especially when you’re just beginning your startup journey. Whether you’re in the idea stage or building on the friends-and-family plan or preparing to pitch investors, it’s imperative to understand the shifting VC funding landscape as you plan... par Anna Heim | Août 18, 2022 | ageing, Apeiron Investment Group, Biotech & Health, business incubators, Christian Angermayer, Companies, economy, investor survey, JME Ventures, longevity, partner, Startups, TC, TechStars, United States, venture
Analysts estimate that the market for “delaying human death” could be worth $610 billion by 2025. But that doesn’t sit well with Christian Angermayer, who co-founded Cambrian BioPharma and Rejuveneron, and whose family office Apeiron Investment Group...
Commentaires récents